Skip to main content
Cancer Biology & Medicine logoLink to Cancer Biology & Medicine
. 2022 May 10;19(7):1109–1110. doi: 10.20892/j.issn.2095-3941.2022.0172

Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors

Yangling Li 1,2, Dongmei Zhou 1, Shuang Xu 1, Mingjun Rao 3, Zuoyan Zhang 4, Linwen Wu 4, Chong Zhang 4,, Nengming Lin 1,2,3,
PMCID: PMC9334766  PMID: 35532134

In the published paper1, errors appeared in Figure 1D on page 391. In Figure 1D, an incorrect gel image was shown for Bcl-xL in NCI-H1299 cells. Figure 1D has been updated to correct the mistake above. The errors do not affect the conclusions of this article. We apologize for the errors and for any confusion that they may have caused.

Figure 1.

Figure 1

(C) NSCLC cells were treated with harmine at the indicated concentrations for 24 h, and the expression of the indicated proteins were detected by Western blot. (D) NSCLC cells were treated with 20 µM harmine for 1, 3, 6, 9, and 12 h, and the expression of the indicated proteins was detected by Western blot.

Reference

  • 1.Li Y, Zhou D, Xu S, Rao M, Zhang Z, Wu L, et al. DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors. Cancer Biol Med. 2020;17:387–400. doi: 10.20892/j.issn.2095-3941.2019.0380. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Biology & Medicine are provided here courtesy of Chinese Anti-Cancer Association

RESOURCES